Reid M. Huber

Board Director

Director

Bellicum Pharmaceuticals, IncTango Therapeutics, Inc.Incyte Corp Rapport Therapeutics, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 1 buy · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€426k

▼ Sales (14 ops.)

€8.8M

Latest filing published 15 Sept 2025 for Rapport Therapeutics, Inc., €426k.

Filing timeline

BuySale

Reid M. Huber

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+13.0%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Reid M. Huber: trading record in brief

Filings by Reid M. Huber span 4 companies, the busiest being Incyte Corp, Bellicum Pharmaceuticals, Inc and Rapport Therapeutics, Inc. We count 45 filings; the first trade dates from 12 November 2014 and the latest from 12 September 2025.

In open-market terms, that means 1 purchase worth €426k on one side and 14 sales worth €8.8M on the other. Netting one side against the other leaves €8.4M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 12 share grants and 18 option exercises. In 2025 alone, the filings show 1 purchase and no sales.

Most recently, on 15 September 2025, the filings show an open-market purchase worth €426k in Rapport Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.